Roche Venture Fund

About The Fund

Roche Venture Fund is a corporate venture capital arm of the Roche Group, headquartered in Basel, Basel-Stadt, Switzerland. With assets under management valued at approximately $330 million, the fund strategically invests in innovative life science companies that are developing new technologies and medicines, offering transformative solutions within the biotech and medical devices sectors. They particularly focus on oncology, a priority given Roche's global leadership in cancer treatments. The fund's investment approach encompasses both early-stage and seed investments in companies that have the potential to provide significant benefits to patients. With an investment range from $600,000 to $3,000,000, Roche Venture Fund empowers entrepreneurs by providing not only capital but also its extensive expertise in the industry. As a corporate VC, their investment thesis aligns with the overarching goals of Roche—to pursue groundbreaking science and improve the lives of patients. The firm brings a commitment to equity investments, seeking to build long-term relationships with their portfolio companies and aid in their development by leveraging Roche's vast resources, global reach, and expertise in the healthcare and pharmaceutical sectors. Roche Venture Fund often acts as a bridge between novel life sciences ventures and the market, helping to scale innovations through the challenging early stages of company growth.